심혈관 중재시술 시장 - 예측(2025-2030년)

The Interventional Cardiology Market is projected to expand from USD 26.096 billion in 2025 to USD 34.742 billion in 2030, registering a 5.89% compound annual growth rate (CAGR).

The global interventional cardiology market is poised for robust growth, driven by the increasing adoption of minimally invasive procedures and the rising prevalence of cardiovascular diseases (CVDs). Interventional cardiology utilizes catheters-thin, flexible tubes inserted into the body-to treat damaged vessels, narrowed arteries, and other heart conditions, offering alternatives to open surgery through procedures like angioplasty and valve repair or replacement. The market is supported by technological advancements in catheter-based devices, which enhance procedural precision and patient outcomes. However, stringent regulatory requirements for device approvals and the high cost of procedures, particularly in developing and underdeveloped economies, pose challenges to market expansion.

Market Drivers

Increasing Prevalence of Cardiovascular Diseases

The global burden of cardiovascular diseases remains a primary driver of the interventional cardiology market. As a leading cause of mortality worldwide, CVDs necessitate advanced treatment options, boosting demand for minimally invasive interventions. The growing incidence of conditions such as coronary artery disease and heart valve disorders is driving the adoption of catheter-based procedures, which offer reduced recovery times and lower risks compared to traditional surgery.

Technological Advancements in Devices

Innovations in interventional cardiology devices, including next-generation stents, balloons, and imaging-guided catheters, are significantly propelling market growth. These advancements improve procedural accuracy, safety, and efficacy, enabling better management of complex cardiovascular conditions. Enhanced device designs, such as bioresorbable stents and advanced valve repair systems, are expanding treatment options, further fueling market demand.

Increasing Health Expenditure Worldwide

Rising global healthcare expenditure, particularly in developed and emerging economies, is supporting the growth of the interventional cardiology market. Increased investments in healthcare infrastructure and access to advanced medical technologies are enabling wider adoption of minimally invasive procedures, driving demand for specialized cardiology devices and expanding market opportunities.

Market Restraints

Stringent Regulatory Requirements

The approval process for interventional cardiology devices is subject to rigorous regulatory scrutiny, which can delay market entry and increase development costs. Compliance with diverse regional standards, particularly in North America and Europe, poses challenges for manufacturers, potentially slowing market growth.

High Cost in Developing Economies

The high cost of interventional cardiology procedures and devices limits accessibility in developing and underdeveloped economies, where healthcare budgets and patient affordability are constrained. This affordability gap restricts market penetration in high-growth regions, hindering overall expansion.

Market Segmentation and Geographical Outlook

The interventional cardiology market is segmented by geography, with North America and Europe leading due to advanced healthcare systems, high CVD prevalence, and robust R&D ecosystems. Asia-Pacific is expected to exhibit significant growth, driven by rising healthcare investments, increasing disease burdens, and improving access to advanced treatments in countries like China and India.

Key Players

Major players in the interventional cardiology market include Medtronic, Stryker, Abbott, B. Braun Melsungen AG, Boston Scientific Corporation, Cordis (A Cardinal Health Company), Edwards Lifesciences Corporation, GE Healthcare, Biosensors International Group, Ltd., and Biotronik, Inc. These companies focus on innovation, strategic partnerships, and portfolio expansion to maintain competitive advantage.

Industry Outlook

The interventional cardiology market is set for sustained growth, driven by the rising CVD burden, technological advancements, and increasing healthcare investments. While regulatory and cost-related challenges persist, the market's alignment with minimally invasive trends and regional growth in Asia-Pacific positions it for significant expansion, offering opportunities for stakeholders to address unmet medical needs.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation

By Device Type

• Stents
• Drug-Eluting Stents (DES)
• Bare-Metal Stents (BMS)
• Bioabsorbable Stents
• Catheters
• Diagnostic Catheters
• Guiding Catheters
• Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloons
• Plain Old Balloon Angioplasty (POBA) Balloons
• Cutting/Scoring Balloons
• Drug-Coated Balloons (DCB)
• Atherectomy Devices
• Plaque Modification Devices
• Guidewires
• Embolic Protection Devices
• Others

By Application

• Coronary Artery Disease
• Heart Valve Disease
• Transcatheter Aortic Valve Replacement (TAVR)
• Transcatheter Mitral Valve Repair/Replacement (TMVR)
• Peripheral Vascular Disease
• Structural Heart Disease
• Atrial Septal Defect (ASD) Closure
• Patent Foramen Ovale (PFO) Closure
• Left Atrial Appendage (LAA) Closure
• Congenital Heart Defects

By End-User

• Hospitals and Clinics
• Ambulatory Surgery Centers (ASCs)
• Specialty Cardiac Centers

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. INTERVENTIONAL CARDIOLOGY MARKET BY DEVICE TYPE

• 5.1. Introduction
• 5.2. Stents
  • 5.2.1. Drug-Eluting Stents (DES)
  • 5.2.2. Bare-Metal Stents (BMS)
  • 5.2.3. Bioabsorbable Stents
• 5.3. Catheters
  • 5.3.1. Diagnostic Catheters
  • 5.3.2. Guiding Catheters
• 5.4. Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloons
  • 5.4.1. Plain Old Balloon Angioplasty (POBA) Balloons
  • 5.4.2. Cutting/Scoring Balloons
  • 5.4.3. Drug-Coated Balloons (DCB)
• 5.5. Atherectomy Devices
• 5.6. Plaque Modification Devices
• 5.7. Guidewires
• 5.8. Embolic Protection Devices
• 5.9. Others

6. INTERVENTIONAL CARDIOLOGY MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Coronary Artery Disease
• 6.3. Heart Valve Disease
  • 6.3.1. Transcatheter Aortic Valve Replacement (TAVR)
  • 6.3.2. Transcatheter Mitral Valve Repair/Replacement (TMVR)
• 6.4. Peripheral Vascular Disease
• 6.5. Structural Heart Disease
  • 6.5.1. Atrial Septal Defect (ASD) Closure
  • 6.5.2. Patent Foramen Ovale (PFO) Closure
  • 6.5.3. Left Atrial Appendage (LAA) Closure
• 6.6. Congenital Heart Defects

7. INTERVENTIONAL CARDIOLOGY MARKET BY END-USER

• 7.1. Introduction
• 7.2. Hospitals and Clinics
• 7.3. Ambulatory Surgery Centers (ASCs)
• 7.4. Specialty Cardiac Centers

8. INTERVENTIONAL CARDIOLOGY MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. By Device Type
  • 8.2.2. By Application
  • 8.2.3. By End-User
  • 8.2.4. By Country
    • 8.2.4.1. USA
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
• 8.3. South America
  • 8.3.1. By Device Type
  • 8.3.2. By Application
  • 8.3.3. By End-User
  • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
• 8.4. Europe
  • 8.4.1. By Device Type
  • 8.4.2. By Application
  • 8.4.3. By End-User
  • 8.4.4. By Country
    • 8.4.4.1. United Kingdom
    • 8.4.4.2. Germany
    • 8.4.4.3. France
    • 8.4.4.4. Spain
    • 8.4.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. By Product Type
  • 8.5.2. By Application
  • 8.5.3. By Country
    • 8.5.3.1. Saudi Arabia
    • 8.5.3.2. UAE
    • 8.5.3.3. Others
• 8.6. Asia Pacific
  • 8.6.1. By Device Type
  • 8.6.2. By Application
  • 8.6.3. By End-User
  • 8.6.4. By Country
    • 8.6.4.1. China
    • 8.6.4.2. Japan
    • 8.6.4.3. India
    • 8.6.4.4. South Korea
    • 8.6.4.5. Taiwan
    • 8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Medtronic
• 10.2. Stryker
• 10.3. Abbott
• 10.4. B. Braun Melsungen AG
• 10.5. Boston Scientific Corporation
• 10.6. Cordis
• 10.7. Edwards Lifesciences Corporation
• 10.8. GE Healthcare
• 10.9. Biosensors International Group, Ltd.
• 10.10. Biotronik, Inc.

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key benefits for the stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations